Amdocs (DOX) Could Be 39% Below Fair Value As Recurring Revenue Anchors The View
Amdocs (DOX) is drawing investor attention after a stretch of weaker share performance. The stock is down 20% over the past month and 22% over the past 3 months, prompting fresh interest in its valuation.
See our latest analysis for Amdocs.
Zooming out, Amdocs’ weak recent momentum extends beyond the past month, with the share price down over the year to date and the 1 year total shareholder return also in decline. This points to fading confidence rather than a short term setback.
If this pullback has you reassessing your tech exposure, it could be a useful moment to see what else is on the radar via the 49 AI infrastructure stocks
With Amdocs trading well below its recent levels despite reporting annual revenue of $4.62b and net income of $545.76m, the key question is whether this slump leaves the stock undervalued or whether the market is already pricing in future growth.
Most Popular Narrative: 39.2% Undervalued
According to the most followed narrative on Amdocs, a fair value of $82.03 is compared against the last close of $49.87. This frames the current slide as a valuation gap rather than just weak sentiment.
Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12 month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.
Curious what keeps this narrative anchored near $80 per share despite a falling stock price and slower revenue forecasts? The explanation focuses on recurring cash flows, steady margins and how those factors feed into long term discounted cash flow assumptions.
Result: Fair Value of $82.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, several risks could challenge this Amdocs thesis, including weaker demand from telecom customers or a sustained shift in spending priorities away from its software and services.
Find out about the key risks to this Amdocs narrative.
Next Steps
If the mixed sentiment around Amdocs has you undecided, take advantage of the current information by reviewing the company’s one or more potential rewards via the 5 key rewards
Looking for more investment ideas beyond Amdocs?
If Amdocs has you rethinking your portfolio mix, do not stop here. Use this moment to compare a wider set of opportunities before the market moves on.
- Target potential upside by scanning for companies flagged as trading below their estimated value through the 44 high quality undervalued stocks.
- Strengthen your income stream by checking stocks with higher yields and resilient payouts using the 9 dividend fortresses.
- Reduce portfolio stress by focusing on companies screened for sturdier finances and healthier fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Amdocs might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com